SyntekaBio, Inc. (KOSDAQ:226330)

SyntekaBio Statistics

Total Valuation

SyntekaBio has a market cap or net worth of KRW 59.36 billion. The enterprise value is 69.03 billion.

Market Cap	59.36B
Enterprise Value	69.03B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

SyntekaBio has 15.26 million shares outstanding. The number of shares has increased by 0.58% in one year.

Current Share Class	15.26M
Shares Outstanding	15.26M
Shares Change (YoY)	+0.58%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	17.18%
Owned by Institutions (%)	0.03%
Float	12.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	44.68
PB Ratio	4.20
P/TBV Ratio	4.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.84
EV / Sales	51.96
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.86

Financial Position

The company has a current ratio of 0.44, with a Debt / Equity ratio of 1.40.

Current Ratio	0.44
Quick Ratio	0.42
Debt / Equity	1.40
Debt / EBITDA	n/a
Debt / FCF	-1.68
Interest Coverage	-4.84

Financial Efficiency

Return on equity (ROE) is -78.61% and return on invested capital (ROIC) is -23.17%.

Return on Equity (ROE)	-78.61%
Return on Assets (ROA)	-17.89%
Return on Invested Capital (ROIC)	-23.17%
Return on Capital Employed (ROCE)	-81.49%
Revenue Per Employee	25.55M
Profits Per Employee	-345.83M
Employee Count	52
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.49% in the last 52 weeks. The beta is 0.58, so SyntekaBio's price volatility has been lower than the market average.

Beta (5Y)	0.58
52-Week Price Change	-11.49%
50-Day Moving Average	4,712.00
200-Day Moving Average	6,524.10
Relative Strength Index (RSI)	39.58
Average Volume (20 Days)	64,635

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SyntekaBio had revenue of KRW 1.33 billion and -17.98 billion in losses. Loss per share was -1,178.57.

Revenue	1.33B
Gross Profit	1.32B
Operating Income	-13.46B
Pretax Income	-17.98B
Net Income	-17.98B
EBITDA	-11.29B
EBIT	-13.46B
Loss Per Share	-1,178.57

Balance Sheet

The company has 10.16 billion in cash and 19.84 billion in debt, giving a net cash position of -9.67 billion or -633.79 per share.

Cash & Cash Equivalents	10.16B
Total Debt	19.84B
Net Cash	-9.67B
Net Cash Per Share	-633.79
Equity (Book Value)	14.12B
Book Value Per Share	925.63
Working Capital	-13.61B

Cash Flow

In the last 12 months, operating cash flow was -11.72 billion and capital expenditures -61.67 million, giving a free cash flow of -11.78 billion.

Operating Cash Flow	-11.72B
Capital Expenditures	-61.67M
Free Cash Flow	-11.78B
FCF Per Share	-772.18

Margins

Gross Margin	99.59%
Operating Margin	-1,013.27%
Pretax Margin	-1,353.66%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

SyntekaBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.58%
Shareholder Yield	-0.58%
Earnings Yield	-30.30%
FCF Yield	-19.85%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SyntekaBio has an Altman Z-Score of -2.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.15
Piotroski F-Score	3